Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study

Wang, YW; Xu, JD; Li, J; Wei, Z; Shi, MJ; Tao, R; Chen, BB; Tian, YY; Zhang, WH; Ma, Y; Sun, LH; Hou, YH; Zhan, QL; Wang, JG; Xue, HW; Liu, P

Liu, P (通讯作者)，Fudan Univ, Zhongshan Hosp, Dept Hematol, Shanghai, Peoples R China.;Xue, HW (通讯作者)，Qingdao Univ, Dept Hematol, Affiliated Hosp, Qingdao, Peoples R China.

ANNALS OF HEMATOLOGY, 2022; 101 (10): 2139

Abstract

Marginal zone lymphoma (MZL) is an uncommon subtype of non-Hodgkin lymphoma (NHL). Combination of rituximab and cladribine (R-2CdA) is a potential opt......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索